Dogwood Therapeutics opened lower at $1.17, compared with its previous close of $1.18. In the last trading session, the stock traded between $1.08 and $1.21. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Dogwood Therapeutics is now worth
$ 38.83
Resulting in a loss of
$ 61.17 (61.17%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.08 (-6.86%)
Day High
$1.21
Day Low
$1.08
Day Open
$1.17
Prev Close
$1.18
Volume
1,17,888
1W Return
5.67%
1M Return
-20.01%
3M Return
-40.14%
6M Return
-34.97%
1Y Return
-80.51%
Fundamentals
Market Cap ($ Mn)
42
PE Ratio
1.19
PB Ratio
1.29
PEG Ratio
-
ROE
-
ROCE
-37.36%
EPS (TTM)
$-0.34
Investment Returns
1 Week
5.67%
1 Month
-20.01%
3 Months
-40.14%
6 Months
-34.97%
9 Months
-64.20%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
19Oct
Dogwood Therapeutics secures $5 million from CKLS subsidiary
Dogwood Therapeutics secured a $5 million investment from a CKLS subsidiary. Shares issued at $1.22 each, extending operational runway through March 2027. Funds support Phase 3 preparations for Halneuron ahead of November 2026 data. Trial involves 239 patients with chemotherapy-induced neuropathic pain.
24 days ago
6Oct
Dogwood Therapeutics to participate in 2026 Maxim Growth Summit
Management to attend 2026 Maxim Growth Summit in New York. Halneuron Phase 2b trial enrollment recently completed. Top-line data readout anticipated for November 2026. CEO Greg Duncan to meet institutional investors one-on-one.
1mo ago
14Sep
Dogwood completes enrollment in Halneuron Phase 2b CINP trial
Dogwood Therapeutics completed enrollment of 239 patients in its Halneuron Phase 2b trial. The enrollment figure meets the upper end of the planned target range for the study. Topline data for the chemotherapy-induced neuropathic pain trial is expected in November 2026. Halneuron holds FDA fast-track designation for treating this unmet medical need.
1mo ago
20Jul
Dogwood enrolls first 200 patients in Halneuron Phase 2b trial
Dogwood Therapeutics announced the enrollment of the first 200 patients in its HAL-CINP Phase 2b trial for Halneuron, a treatment for chemotherapy-induced neuropathic pain. The randomized study aims to enroll up to 240 patients across 25 U.S. sites, with primary endpoints measuring pain intensity changes over four weeks. The company reports positive interim separation from placebo and anticipates top-line data in the fall of 2026.
3mo ago
30Jun
Dogwood Therapeutics appoints OrbiMed's Iain Dukes as SAB Chair
Dogwood Therapeutics has appointed Iain Dukes, Ph.D., as Chair of its Scientific Advisory Board to guide the development of its pain and neuropathy pipeline. Dr. Dukes, a Venture Partner at OrbiMed, brings deep experience in ion channel therapeutics. The company is advancing Halneuron in Phase 2b and SP16 in Phase 1b, supported by FDA clearance and National Cancer Institute funding.
